Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Rabbit Anti-Thymocyte Globulin in Diffuse Systemic Sclerosis
NCT00016458Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2000
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit and cyclophosphamide in systemic sclerosis (SSc), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Toxicity of cyclophosphamide and rabbit anti-thymocyte globulin at 1 year and Efficacy in terms of controlling disease at 1 year. Started Jun 2000; status: completed.
02
Drugs
antithymocyte globulin rabbitcyclophosphamide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00016458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016458.